The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV,[1][2] is one of two
inactivated virusCOVID-19 vaccines developed by
Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group).[3] The other inactivated virus COVID-19 vaccine developed by Sinopharm is the
BIBP vaccine (BBIBP-CorV) which is comparably more successful. 1 billion doses are expected to be produced per year.
In May 2021, peer-reviewed results published in
JAMA of Phase III trials in
United Arab Emirates and
Bahrain showed that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). 12,743 people received the vaccine and 12,737 people received the placebo in these trials.[3]
Manufacturing
In June 2021, a new factory started production with the capacity to manufacture 1 billion doses annually.[7]
History
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by
Sinopharm's Beijing Institute of Biological Products (BIBP)[8] and the Wuhan Institute of Biological Products (WIBP).[9] Both vaccines are chemically-inactivated whole virus vaccines for
COVID-19.[citation needed]
On August 13, 2020, the
Wuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated
immunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[9]
Clinical trials
In March 2021,
Cayetano Heredia University running the BIBP and WIBP trials in Peru announced they were seeking to suspend and unblind participants in the WIBP trials for lower efficacy and offer the participants the BIBP vaccine instead, which was showing efficacy.[10]
On February 25, 2021, China approved the vaccine for general use.[11]
According to The New York Times, the vaccine is only approved for limited use in
United Arab Emirates.[12] On August 19, 2021, the Philippines approved the vaccine for emergency use authorization.[13]